Datasets
Buyer room
RXALMANAC.COMManage supplier listing
Data Unveil — Aggregated specialty-pharmacy and hub patient-journey dataset: patient-level records stitched across more than 100 channel partners — specialty pharmacies, hubs, copay and free-drug programmes — spanning referral, therapy start, dispense, reimbursement (prior authorisation, affordability, denial), adherence and persistence, joined to claims, prescription, electronic health record, laboratory, formulary and policy, and provider and organisation reference data. The differentiated slice is the reimbursement-and-abandonment layer: why a prescribed specialty therapy fails to reach th…
supplier index read from their site
Aggregated specialty-pharmacy and hub patient-journey dataset: patient-level records stitched across more than 100 channel partners — specialty pharmacies, hubs, copay and free-drug programmes — spanning referral, therapy start, dispense, reimbursement (prior authorisation, affordability, denial), adherence and persistence, joined to claims, prescription, electronic health record, laboratory, formulary and policy, and provider and organisation reference data. The differentiated slice is the reimbursement-and-abandonment layer: why a prescribed specialty therapy fails to reach the patient, and at which step, which no claims-only source observes. Accessible through the SCRAII reporting layer and enriched by privacy-preserving linkage to external sources.
From 6 yearsCoverage Health CareAsset class Equities
Sample, licence terms, pricing and eval results when Data Unveil publishes them. Until then, discover alternatives today with a 7-day trial.
Start 7-day trial →What buyers ask about Data Unveil, answered from this page.
Data Unveil — Aggregated specialty-pharmacy and hub patient-journey dataset: patient-level records stitched across more than 100 channel partners — specialty pharmacies, hubs, copay and free-drug programmes — spanning referral, therapy start, dispense, reimbursement (prior authorisation, affordability, denial), adherence and persistence, joined to claims, prescription, electronic health record, laboratory, formulary and policy, and provider and organisation reference data. The differentiated slice is the reimbursement-and-abandonment layer: why a prescribed specialty therapy fails to reach th…
Data Unveil offers (Alternative, Reference, Supply Chain) — More than 3 million specialty patients across 100+ brands and 100+ data partner feeds (vendor-stated breadth anchors). Inferred row volume: at tens to low hundreds of records per patient across claims, dispensing, referral, reimbursement and contact events, an estimated 500 million to 2 billion underlying rows, with the reimbursement and prior-authorisation layer the sparsest and most valuable component. The row count is an inference from the stated patient and brand counts, not a vendor figure..
Market access and payer research: prior-authorisation friction benchmarking by payer and product, denial-cause trend monitoring, payer-latency measurement. Commercial and brand: launch readout on real access performance, channel-routing and specialty-pharmacy performance comparison, gross-to-net and leakage support. Patient services: abandonment root-cause and intervention targeting, persistence modelling by therapy area. Machine learning: labelled journey-outcome sequences for patient-lifecycle state models — abandonment, adherence, and step-level failure prediction in specialty therapy — a supervised dataset with objective rather than surveyed outcomes; plus payer-decision outcome data for models predicting coverage approval.
The data is with 6 years of history.
Coverage spans US; Pharmaceuticals, Health Care Technology; alternative, reference, supply_chain; equities.
Data Unveil has not added their own details yet. Not yet on file: